

Centre for Youth Substance Abuse Research  
Annual Report

# 2019



Director of Centre Report .....	3
Mission Statement and Aims .....	6
Achievements, Awards and Honours .....	10
Key Centre Funding and Research Outcomes .....	12
Research Grants, Contracts and Publications .....	23
Our People .....	35
Major Partners and Collaborators .....	40

# Director of Centre Report



*Above* Jason Connor, Director

The Centre for Youth Substance Abuse Research (CYSAR) established in 2008 and located in the Faculty of Health and Behavioural Sciences (HABS) at The University of Queensland (UQ) is the only Australian research centre focusing exclusively on young people and substance use.

In February 2019 the Federal Health Minister named CYSAR as one of four national research centres successful in the Commonwealth Department of Health's Drug and Alcohol Program Grant (2019-2022). This funding allows CYSAR and our affiliated Lived Lived Well Group at UQ School of Psychology to continue our nationally and internationally impactful work across areas of harm reduction, substance supply reduction, youth epidemiology, and alcohol and drug policy. These areas reflect key research priorities of the Federal Government's National Drug Strategy 2017-2026.

## I am proud of the *achievements* of our staff in 2019.

Dr Gary Chan won a highly competitive five-year National Health and Medical Research Council (NHMRC) Investigator Fellowship (Emerging Leadership Level 1). Dr Matt Gullo, an NHMRC Medical Research Future Fund (NHMRC MRFF) Translating Research into Practice (TRIP) Fellow, was promoted to Associate Professor in September, to take effect in January 2020.

In 2019 CYSAR produced 113 peer reviewed publications from salaried staff and 15 national and international invited talks. CYSAR's research outcomes were presented in 100 peer reviewed articles, 13 books and book chapters, as well as 16 published abstracts, oral presentations and posters including 10 papers at six international meetings. CYSAR currently has seven high performing PhD students, the majority holding competitive scholarships.

Two of our students, Dr Nina Pocuca and Dr Zoe Papinczak, completed Doctor of Philosophy programs in 2019. CYSAR will welcome four new RHD students to its new freestanding premises in 17 Upland Road in 2020 with two set to begin in January.



*Top right* Prof Jason Connor and Prof Leanne Hides

*Bottom right (L to R)* Dr Gary Chan, Dr Catherine Quinn, Dr Janni Leung, and Prof Leanne Hides

We warmly thank *Professor Christina Lee* for her vital support above and beyond her Board Chair service over the last four years.

In 2019, Professor Christina Lee stepped down as CYSAR Advisory Board Chair following her retirement after 36 years as a full time academic. The CYSAR Advisory Board and staff look forward to welcoming the next Board Chair in 2020.

This 2019 annual report details the research achievements of our staff and the impact they have made on youth substance use policy, prevention and treatment.


**Jason Connor**  
**Director, CYSAR**




*Above* Emeritus Professor Christina Lee, UQ, Faculty of Health and Behavioural Sciences

# Mission Statement *and* Aims

2





## *Finding solutions, improving futures, partnering with young people.*

CYSAR is one of only four Commonwealth-funded alcohol and other drug research centres in Australia and the only centre dedicated to youth- focused research.

CYSAR was established with philanthropic funding in 2008 through the Graeme Wood Foundation. Mr Wood's vision was for the Centre to conduct world class research that would reduce the prevalence and severity of drug and/or alcohol misuse in Australian communities; enhance research capacity informing national efforts to address substance misuse; and enhance our knowledge on treatment approaches for emerging drugs of concern and innovative treatment models.

The Centre continues this vision through a strong track record of competitive external research funding, administered through the UQ Faculty of Health and Behavioural Sciences. In 2019, the Commonwealth renewed its funding for CYSAR for the next three years.

Our mission is to promote the *health and wellbeing of young people* by increasing Australia's capacity to respond effectively to any harm arising from substance use.



Understand the pathways by which young people engage in substance misuse



Be at the cutting edge of research into new and innovative ways of preventing and treating substance misuse among young people



Make significant and tangible improvements to youth service provision



Positively influence state and national approaches to youth substance misuse prevention and treatment through information dissemination, policy refinement and public advocacy




Ensure youth have a voice and input into the research directions of the Centre

CYSAR has a strong track record of delivering high quality research, with translatable outcomes aimed at reducing the impact of substance use on young people, their families and the wider community resulting in significant national health and social economic benefits. Strategic guidance and support are provided by an Advisory Board that has a diverse wealth of experience in health, clinical and youth research, advocacy, media and government and non-government youth alcohol and drug service provision.

CYSAR researchers are regularly invited to deliver national and international keynote presentations, as well as disseminate their work into clinical services through the delivery of training workshops and clinical resources such as treatment manuals. Several hold adjunct clinical appointments in alcohol and drug services, facilitating research translation.

CYSAR has extensive collaborations and links with other national and international researchers in the alcohol and other drug field and well-established industry and clinical partners across the drug and alcohol, mental health, emergency, housing and social support sectors. Executive officers of many of these services are represented on the CYSAR Advisory Board and have formal UQ affiliate joint appointments with the Centre.



3

# Achievements, Awards *and* Honours





- Dr Matthew Gullo was awarded an NHMRC Medical Research Future Fund (MRFF) Translating Research into Practice (TRIP) Fellowship for his project entitled: “iAx: Instant assessment and personalised feedback in alcohol use disorder”.
- Dr Gary Chan was awarded a NHMRC Investigator Fellowship, Emerging Leadership Level 1 for “E-cigarettes and vaping: holy grail of tobacco control or gateway to a public health disaster?”
- Dr Gary Chan received the UQ HaBS Faculty Staff Award for Early Career Research Excellence.
- Prof Jason Connor received the UQ HaBS Faculty Staff Award for Research Mentorship.

*Top left* Centre Director Professor Jason Connor receives Research Mentorship award from Faculty Executive Dean Professor Bruce Abernethy

*Bottom left* Dr Gary Chan in Hobart giving “wise career and science advice” at the APSAD early and mid-career research networking event praised by International Keynote speaker Professor Keith Humphries

4




# Key Centre Funding *and* Research Outcomes

## Refunded by Commonwealth

In February, Federal Health Minister Hunt announced that CYSAR would share in \$24 million in research funding allocated across four National Addiction Research Centres over the next three years under the Drug and Alcohol Program of the Commonwealth Department of Health as an Alcohol and Other Drug Research Centre of Excellence for “Understanding, preventing and treating youth substance abuse”. The grant is co-led by Professor Jason Connor (CYSAR, HABS) and Professor Leanne Hides (CYSAR Affiliate & Deputy Director, LLW Psychology, HABS). The funding extends the initial two-year Alcohol and Other Drug Research Grant awarded to CYSAR in 2017. The announcement reflects the Governments’ strong support to continue the internationally regarded research produced by CYSAR. Staff over-delivered on all projects funded by the Commonwealth in the first two years of funding.

## New and Continuing Research Funding

CYSAR paid staff were Chief Investigators on eight new successful grants and tenders, collectively worth \$5,804,770. Dr Matt Gullo began a two year NHMRC Translating Research into Practice (TRIP) Fellowship (\$181,000) for his project entitled: “iAx: Instant assessment and personalised feedback in alcohol use disorder” and Professor Connor and Dr Gullo began two year Project and Innovation Grants through the Metro South Health Research Support Scheme amounting to \$100,000. Professor Wayne Hall is a Chief Investigator on a 4 year NHMRC Project grant titled “Common mental and substance use disorders in a 28-year follow-up of a community cohort: identification of preventive strategies from adolescence to early midlife” worth \$1.14M led by Professor George Patton and colleagues at the University of Melbourne.



*Above* Early Career Researchers are coauthors on major Lancet review with Professor Wayne Hall

## Publications *and* International Meetings

CYSAR research staff authored or co-authored 113 peer reviewed publications from salaried staff and 15 national and international invited talks. CYSAR's research outcomes were also presented in 15 published abstracts, oral presentations and posters including 10 papers at six international meetings.

## Lancet Series

Professor Wayne Hall, CYSAR Research Fellow Dr Daniel Stjepanović and LLW/CYSAR Affiliate Research Fellow Dr Janni Leung, contributed to a new Lancet review series: *Using evidence to better respond to drug problems* – a call for action. Prof Hall was an author on two of the four papers and lead author of “Public health implications of legalizing the production and sale of cannabis for medicinal and recreational use”, which was his third major invited Lancet review of the health impacts of cannabis since 1998. Prof Hall attended the Lisbon Addictions conference and participated in a plenary big debate session on cannabis policy, as well as three symposia including the Lancet series.

Dr Gullo reported results of the first RCT of the additive effectiveness of mindfulness meditation to school-based alcohol prevention at the World Congress of Behavioural and Cognitive Therapies in Berlin in July. There is significant investment in mindfulness-based school prevention for mental health problems. However, as predicted by the new biosocial Cognitive Theory of adolescent substance use (bSCT) developed by Dr Gullo and findings from Dr Gullo's human preclinical work, mindfulness was found to not be as effective as initially thought in reducing adolescent drinking. This has important implications for school-based alcohol prevention.

Also at this meeting CYSAR Board member and past Deputy Director Prof Kavanagh reported a 50% reduction in drinking from the NHMRC funded 'Trial of a new low-cost treatment to support self-management of Alcohol Use Disorder: Functional Imagery Training' he leads with CYSAR co-investigators Prof Connor, Dr Gullo and LLW colleagues.

*Top right* Dr Janni Leung at Lancet offices in London for meeting on the cannabis review

*Bottom right* Dr Daniel Stjepanović shares his expertise in systematic review methods at a workshop for RHD students



CYSAR continued its collaboration with HABS Faculty Centre QAEHS (Qld Alliance for Environmental Health Sciences) in wastewater studies, specifically in assessment of their role in evaluating the impact of alcohol and drug supply and regulatory policies.


Prof Connor co-authored a paper with QAEHS researchers on “New approach for the measurement of long-term alcohol consumption trends: application of wastewater-based epidemiology in an Australian regional city”.

Prof Hall holds a 0.2 appointment in QAEHS and in 2019 co-authored several papers exploring the potential of wastewater based epidemiology using samples taken during Australian census week 2016 and comparing consumption of a range of stimulant drugs between an Australian region and two European cities. Prof Hall and colleagues were interviewed by the Medical Journal of Australia on trends in methamphetamine detected by wastewater analyses in Southeast Queensland.



Above A/Professor Matthew Gullo receiving Metro South funding to conduct iAx projects

Professor Connor and Dr Gullo were funded by Metro South Health to conduct projects on treatment innovation with a technological focus, one on a new behavioural treatment for alcoholic hepatitis and another using new electronic instant assessment and feedback system (iAx). CYSAR RHD students have already published the first of several RCTs on the use of these innovative technology service collaborations to improve clinical practice.



## National Meeting

There was a strong showing from CYSAR/LLW at the Australasian Professional Society on Alcohol and other Drugs (APSAD) November meeting in Hobart. Dr Catherine Quinn, CYSAR Affiliate Fellow in the LLW Psychology group gave a Keynote address and received the national Early Career Researcher award. LLW group researchers led by Prof Leanne Hides presented LLW/ CYSAR research results in a Symposium on “Novel approaches to address the complexities of youth substance use”. Dr Janni Leung’s poster presented CYSAR/LLW work on the risk of cannabis use disorders. RHD students Sarah Bryant and Zoe Papinczak gave oral presentations; Vivian Chiu’s examination of Australian attitudes toward cannabis legalisation was selected for poster highlight. Dr Gary Chan’s Early Career Researcher ECR workshop emphasising the critical role of mentorship was praised by International Keynote Professor Keith Humphreys from Stanford University.

*Clockwise* Prof Leanne Hides and Dr Catherine Quinn; Dr Janni Leung; and Vivian Chiu


## National Consultation Invitations

### National Alcohol Treatment Guidelines (NATG)

#### Update in progress

The National Alcohol Treatment Guidelines were last updated in 2009 and the current update is led by Prof Paul Haber, Head of Addiction Medicine, University of Sydney and Clinical Director, Royal Prince Alfred Hospital. Professor Connor is a member of the National Strategic Reference Group. Dr Gullo and Honorary Professor John Saunders were commissioned to lead chapter updates in their respective areas of expertise. All attended a Sydney symposium to present initial findings and received positive feedback on their presentations.

The CYSAR Director and the leader of the LLW Group are members of the Federal Government's Alcohol and Drug Centres of Excellence Strategic Reference Group, tasked with guiding evidence-based policy on substance use in Australia. Professor Wayne Hall is Chair of the International Advisory Board of the Australian Centre for Cannabinoid Clinical and Research Excellence which is a National Health and Medical Research Council Centre of Excellence. Professor Wayne Hall is a member of the Federal Government's Australian Advisory Committee on Medical Uses of Cannabis.



*Images* Professor Wayne Hall is frequently invited to comment on cannabis policy in the scientific press



## International Consultation Invitations

Dr Gary Chan undertook a two month consultancy with the UN Office on Drugs and Crime from March-April 2019. He completed a report on opium cultivation in low income countries to assist government policy on helping opium farmers transition into growing legal crops.

Prof Wayne Hall published a Thematic Chapter on medical cannabis commissioned by the International Narcotics Control Board (INCB) for their widely read Annual Report. Thematic Chapters of the INCB, a quasi-judicial UN drug treaty monitoring agency, are reserved for major contemporary policy topics. Prof Hall's commissioned report to EU drugs agency the European Monitoring Centre on Drugs and Drug Addiction released in December 2018 informed the deliberations of the European Parliament in their Resolution on the Use of Cannabis for Medicinal Purposes of 13 February 2019.

Prof Hall provided an expert briefing to the World Health Organization Meeting of Technical Experts on Cannabis in Geneva via teleconference. He has been invited to lead an update on the public health effects of cannabis use in 2020. Prof Hall led the most recent review published in 2016.

## Research Students

CYSAR graduated its 6th and 7th PhD students Nina Pocuca and Zoe Papinczak, who were awarded their PhDs respectively for “Examination of personality risk profiles and alcohol use in young people” (LLW, formerly CYSAR QUT based Principal Adviser Leanne Hides, Associate Advisor Catherine Quinn) and “A bioSocial cognitive model of youth cannabis dependence” (Principal Advisor Matt Gullo, Associate Advisor Jason Connor).

The majority of the seven continuing PhD students hold Australian Government Research Training Program Scholarships. In 2019 student-led papers were published, accepted, or submitted and subsequently published in highly ranked journals such as *Addiction*, *Journal of Abnormal Child Psychology*, *Journal of Studies on Alcohol and Drugs*, *Personality and Individual Differences*, and *Sexual & Reproductive Healthcare*.

CYSAR will welcome four new PhD students in 2020 with two to start in January.

# Media

Prof Wayne Hall was interviewed in March by Italian newspaper Corriere della Sera on substance use and youth mental health informed by discussion of a new book, The Age of Onset of Mental Disorders: Ethiopathogenetic and Treatment Implications with several chapters contributed by CYSAR.

Dr Chan and Prof Hall's paper in Addiction "Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo Simulation" (that 16% of cannabis users accounted for 80% of total consumption) received significant media attention.

Prof Hall et al's editorial "Miscommunication about the causes of the US outbreak of lung diseases in vapers by public health authorities and the media" following his CYSAR seminar in December which attracted a large contingent of Queensland Health senior staff was reportedly in the top 5% of all research outputs scored by Altmetric and the third highest scoring output published by Drug and Alcohol Review.

Shortly after the release of the Lancet series papers at the Lisbon Addictions meeting in October, Prof Hall's Lancet Psychiatry review "Cannabinoids for the treatment of mental disorders" received a large amount of media attention including in New Scientist, The Huffington Post, Forbes, The Scientist, The Guardian, Pharmazeutische Zeitung, The Independent, the Daily Mail, Die Welt and Time magazine.



Images Italian newspaper Corriere della Sera interviews Prof Hall, "uno dei maggiori esperti al mondo di questi problemi"



Left Symposium "Coming of Age"  
 Below (L to R) Dr Valentina Lorenzetti,  
 Professor Jason Connor, Ms Sarah Yeates,  
 Dr Daniel Stjepanović, Dr James Kesby, A/  
 Professor Simon Denny, Professor Wayne  
 Hall, Dr Eva Hoch, Professor Leanne Hides

## CYSAR Seminars

CYSAR hosted a Symposium on 4 September on Cannabis and the Brain at QBI, chaired by Professor Connor, to mark CYSAR's 10-year anniversary. Interstate and international speakers Dr Eva Hoch and Dr Valentina Lorenzetti along with Professor Wayne Hall and high profile UQ researchers Professor John McGrath and Professor Leanne Hides addressed topics at the intersection between the brain sciences and the study of youth substance use:

(1) the implications of the legalisation of cannabis in Canada, Uruguay and the USA for the mental health and cognitive development of young people; and (2) the reasons for and responses to the co-occurrence of alcohol and other drug use and serious mental disorders in young people and their development toward adulthood.

CYSAR and UQ School of Psychology hosted a lunchtime seminar on 5 December from Professor Wayne Hall moderated by CYSAR Acting Director Prof Leanne Hides on "The US outbreak of vaping-related lung diseases: probable cause and policy responses". This seminar on an issue of significant contemporary public concern received significant interest from Psychology RHD students and Queensland Health. More than 40 attended including senior Queensland Health Executives.



## Government Reports

CYSAR has delivered two expert briefing reports for the Commonwealth Department of Health (under its contractual Ad Hoc 'required on short notice' provision) on the potential risks posed by low-and 'zero'-alcohol beverages and trends on emerging illicit drugs of concern to assist in interdepartmental priority setting. CYSAR also submitted invited feedback on the Commonwealth Government's Ice Strategy.

## Collaborative Report

CYSAR joined with other national drug and alcohol research centres in a report led by NDRI, Curtin University with the participation of NSW Bureau of Crime Statistics and Research and SA Centre for Economic Studies on quantifying the social costs of pharmaceutical opioid misuse and illicit opioid use to Australia in 2015/6. Strong media interest is anticipated for the report's scheduled appearance in early 2020.



# Research Grants, Contracts *and* Publications

5



## New in 2019

Chief Investigators	Years	Title	Funding Source	Grant Type	Amount Awarded
Gullo	2019-2020	iAx: Instant assessment and personalised feedback in alcohol use disorder	Medical Research Future Fund - Translating Research into Practice	NHMRC TRIP MRFF Fellowship- Next Generation Clinical Researchers Program	\$181,000
Chan	2020-2024	E-cigarettes and vaping: holy grail of tobacco control or gateway to a public health disaster?	National Health and Medical Research Council	Investigator- Emerging Leadership Level 1	\$639,750
Connor, Hides	2019-2022	Understanding, preventing and treating youth substance abuse (II- renewal)	Commonwealth Department of Health	Alcohol and Other Drug Research Centre of Excellence, Drug and Alcohol Program	3,700,000
Patton, Moreno-Betancur, Butterworth, Hall, Borschmann, Moschion, Moran, Campbell	2019-2022	Common mental and substance use disorders in a 28-year follow-up of a community cohort: identification of preventive strategies from adolescence to early midlife	National Health and Medical Research Council	Project Grant	\$1,143,950
Connor, Clark, Feeney, Gullo, Holtman	2019-2020	When drugs don't work: tailored behavioural intervention for alcoholic hepatitis	Metro South Health Research Support	Project Grant	\$75,000
Gullo, Connor, Feeney	2019-2020	Enhancing assessment and progress monitoring in alcohol use disorder treatment	Metro South Health Research Support	Innovation Grant	\$25,000
Elphinston, Connor, Sterling, Fatehi	2020-2021	Co-design, development, and feasibility of a digitally- enabled personalised brief intervention for chronic pain and co- occurring prescription opioid misuse	Metro South Health Research Support	Research Support Scheme Innovation Grant	\$75,000
Hall	2019	Health impacts of cannabis	World Health Organization	Consultancy	\$40,000

## Active (Continuing) in 2019

Chief Investigators	Years	Title	Funding Source	Grant Type	Amount Awarded
Chan	2016-2019	Pathways to multiple substance use: informing the next generation of prevention science	The University of Queensland	UQ Fellowships - Early Career Researcher	\$197,800
Connor, Hides	2017-2019	Understanding, preventing and treating youth substance abuse	Commonwealth Department of Health	Alcohol and Other Drug Research Centre of Excellence, Drug and Alcohol Program	\$2,315,000
Connor, on behalf of CYSAR	2013-2017; extended to 2020	Gift to the Centre for Youth Substance Abuse Research from Graeme Wood and Andrew Brice	The University of Queensland Endowment Fund	Philanthropic Gift	\$2,000,180
Kavanagh, Graves, Connor, Hides, Gullo, Connolly, Andrade, May	2016-2019	A new, low- cost e-health treatment for Alcohol Use Disorder using mental imagery	National Health and Medical Research Council	Project Grant	\$895,000
Borland, Gartner, Hall, Yong, Mundy, Courtney	2016-2020	Understanding the impacts of vaporised nicotine products on smoking in Australia	National Health and Medical Research Council	Project Grant	1,655,000
Gallagher, Connor, Loveday, Ballantyne	2016-2019	Active and interactive analysis of prescription data for harm minimisation	Australian Research Council	Linkage Project in Partnership with Queensland Health	\$191,000 plus \$200,000 to partner
Rundle- Thiele, Arli, Kubacki, Connor, Gullo, Percy	2016-2019	Changing Australian drinking: a comprehensive social marketing program	Australian Research Council	Linkage Project in partnership with Catholic Education	\$234,000 plus \$162,000 to partner
Hammond, Hall, Pacula, George, Rehm, Werb, Boudreau, Wadsworth, Leos-Toro, Porath- Waller, Elliot	2018-2023	Cannabis legalization: impact on prevalence and risk behaviours among young people in Canada	Canadian Institutes of Health Research	Project Grant	\$1,695,000

## 2019 Research Publications

### Full Peer Reviewed Manuscripts

1. Adewumi AD, Maravilla JC, Alati R, Hollingworth SA, Hu X, Loveday B, **Connor JP**. Multiple opioid prescribers: a genuine quest for treatment rather than aberrant behaviour. A two-decade population-based study. *Addictive Behaviors*; submitted December 17: <https://doi.org/10.1016/j.addbeh.2020.106458>.
2. **Anderson LE, Connor JP**, Voisey J, Young RMcD, **Gullo MJ**. The unique role of attachment dimensions and peer drinking in adolescent alcohol use. *Personality and Individual Differences* 2019; 149: 118-22.
3. **Anderson LE**, Dingle GA, O’Gorman B, **Gullo MJ**. Young adults’ sexual health in the digital age: perspectives of care providers. *Sexual & Reproductive Healthcare*; submitted October 1: <https://doi.org/10.1016/j.srhc.2020.100534>.
4. Bao Y, Larney S, Peacock A, Colledge S, Grebely J, Hickman M, Degenhardt L, **Leung J**. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: a systematic review and meta-analysis. *International Journal of Drug Policy* 2019; 70: 87-93.
5. Barnett A, O’Brien K, **Hall WD**, Carter A. Support for the psychosocial, disease and brain disease models of addiction: A survey of treatment providers’ attitudes in Australia, the UK, and U.S. *Journal of Substance Abuse Treatment*; submitted October 16: <https://doi.org/10.1016/j.jsat.2020.108033>.
6. Black N, Stockings E, Campbell G, Tran L, Zagic D, **Hall WD**, Farrell M, Degenhardt L. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. *Lancet Psychiatry* 2019; 6: 995-1010.
7. Bulley A, Miloyan B, Pepper G, **Gullo MJ**, Henry J, Suddendorf T. Cuing both positive and negative episodic foresight reduces delay discounting but does not affect risk-taking. *Quarterly Journal of Experimental Psychology* 2019; 72: 1998-2017.
8. Carter A, Richards L, Aphthorp D, Azghadi M, ..., **Hall WD**, ..., Levy N, Mattingley J, et al. A neuroethics framework for the Australian Brain Initiative. *Neuron* 2019; 101: 365-9.
9. **Chan GCK**, Butterworth P, Becker D, Degenhardt L, Stockings E, **Hall WD**, Patton G. Longitudinal patterns of amphetamine use from adolescence to adulthood: a latent class analysis of a 20-year prospective study of Australians. *Drug and Alcohol Dependence* 2019; 194: 121-7.
10. **Chan GCK, Connor JP, Hall WD, Leung J**. The changing patterns and correlates of population-level polysubstance use in Australian youth: a multi-group latent class analysis of nationally representative samples spanning 12 years. *Addiction* 2019; August 30: <https://doi.org/10.1111/add.14761>.
11. **Chan GCK, Hall WD**. Estimation of the proportion of population cannabis consumption in Australia that is accounted for by daily users using Monte Carlo Simulation. *Addiction*; accepted November 20: <https://doi.org/10.1111/add.14909>.
12. **Chan GCK, Leung J**, Gartner C, Yong H, Borland R, **Hall WD**. Correlates of electronic cigarette use in the general population and among smokers in Australia - findings from a nationally representative survey. *Addictive Behaviors* 2019; 95: 6-10.
13. **Chan GCK, Leung J, Hall WD**. Non-medical use of pharmaceutical opioids with and without other illicit substances in Australia: prevalence and correlates. *Drug and Alcohol Review* 2019; 38: 151-8.
14. **Chan GCK**, Morphett K, Gartner C, **Leung J**, Yong H, **Hall WD**, Borland R. Predicting vaping uptake, vaping frequency and ongoing vaping among daily smokers using longitudinal data from the International Tobacco Control (ITC) Four Country Surveys. *Addiction* 2019; 114 Suppl 1: 61-70.
15. Choi P, Tscharke B, Samanipour S, **Hall WD**, Gartner C, Mueller J, Thomas K, O’Brien J. Social, demographic, and economic correlates of food and chemical consumption measured by wastewater-based epidemiology. *Proceedings of the National Academy of Sciences of the USA* 2019; 116: 21864-73.
16. **Coates JM, Gullo MJ**, Feeney GFX, Young RMcD, Dingle G, Clark P, **Connor JP**. Craving mediates the effect of impulsivity on lapse-risk during alcohol use disorder treatment. *Addictive Behaviors*; accepted December 30: <https://doi.org/10.1016/j.addbeh.2019.106286>.
17. Dawson A, Michael J, Dilkes-Frayne E, **Hall WD**, Dissanayaka N, Carter A. Capacity, control and responsibility in Parkinson’s disease patients with impulse control disorders: views of neurological and psychiatric experts. *International Journal of Law and Psychiatry* 2019; 65: 101343.
18. **de Andrade DF**, Spittal M, Snow K, Taxman F, Crilly J, Kinner S. Emergency health service contact and reincarceration after release from prison: a prospective cohort study. *Criminal Behaviour and Mental Health* 2019; 29: 85-93.

19. Degenhardt L, Wolfe D, **Hall WD**, Hickman M, Chang J, Bruneau J, Farrell M, Griffiths P. Strategies to reduce drug-related harm: responding to the evidence base. *Lancet* 2019; 394: 1490-3.
20. Devilly G, **Hides L**, Kavanagh DJ. A big night out getting bigger: alcohol consumption, arrests and crowd numbers, before and after legislative change. *PLoS ONE* 2019; 14: e0218161.
21. **Dietrich T**, Rundle-Thiele S, Kubacki K, Durl J, **Gullo MJ**, Arli D, **Connor JP**. Virtual reality in social marketing: a process evaluation. *Marketing Intelligence & Planning* 2019; 37: 806-20.
22. Dingle G, Haslam C, Best D, **Chan GCK**, Staiger P, Savic M, Beckwith M, Mackenzie J, Bathish R, Lubman D. Social identity differentiation predicts commitment to sobriety and wellbeing in residents of therapeutic communities. *Social Science and Medicine* 2019; 237: 112459.
23. Fischer B, Bullen C, **Hall WD**. A call for greater policy and regulatory coherence for an expanding menu of legal psychoactive substances. *Drug and Alcohol Review*; submitted October 2: <https://doi.org/10.1111/dar.13071>.
24. Fischer B, Jones W, **Hall WD**, Kurdyak P. Potential public health impacts of medical cannabis availability on opioid-related harms? Urgent but un-answered questions from Canada. *International Journal of Drug Policy* 2019; 73: 96-9.
25. Fischer B, Lee A, O'Keefe-Markman C, **Hall WD**. Initial indicators of the public health impacts of non-medical cannabis legalization in Canada. *EClinicalMedicine* (a *Lancet* publication) in press: <https://doi.org/10.1016/j.eclinm.2020.100294>.
26. Fowler J, **Gullo MJ**, Elphinston R. Impulsivity traits and Facebook addiction in young people and the potential mediating role of coping styles. *Personality and Individual Differences*; submitted December 16: <https://doi.org/10.1016/j.paid.2020.109965>.
27. Gartner C, Bonevski B, **Hall WD**. Miscommunication about the causes of the US outbreak of lung diseases in vapers by public health authorities and the media. *Drug and Alcohol Review*; accepted December 2: <https://doi.org/10.1111/dar.13024>.
28. Gisev N, Nielsen S, Campbell G, Santo T, Mant A, Bruno R, Cohen M, **Hall WD**, Larance B, Lintzeris N, Farrell M, Degenhardt L. Antidepressant use among people prescribed opioids for chronic noncancer pain. *Pain Medicine* 2019; 20: 2450-8.
29. Goulding N, Hickman M, Reid M, Amundsen E, Baz-Lomba J, O'Brien J, Tschärke B, de Voogt P, Emke E, Kuijpers W, **Hall WD**, Jones H. A comparison of trends in wastewater-based data and traditional epidemiological indicators of stimulant consumption in three locations. *Addiction* 2019; November 29: <https://doi.org/10.1111/add.14852>.
30. Graham M, Lucas CJ, Schneider J, Martin JH, **Hall WD**. Translational hurdles with cannabis medicines. *Pharmacoepidemiology and Drug Safety*; submitted December 30: <https://doi.org/10.1002/pds.4999>.
31. Gravely S, Driezen P, Smith DM, Borland R, Lindblom EN, Hammond D, McNeill A, Hyland A, Cummings KM, **Chan GCK**, Thompson ME, Boudreau C, Martin N, Ouimet J, Loewen R, Quah ACK, Goniewicz ML, Thrasher JF, Fong GT. International differences in patterns of cannabis use among adult cigarette smokers: Findings from the 2018 ITC Four Country Smoking and Vaping Survey. *International Journal of Drug Policy*; in press: <https://doi.org/10.1016/j.drugpo.2020.102754>.
32. Gray R, Kelly P, Beck A, Baker A, Deane F, Neale J, Treloar C, **Hides L**, Manning V, Shakeshaft A, Kelly J, Argent A, McGlaughlin R. A qualitative exploration of SMART Recovery meetings in Australia and the role of a digital platform to support routine outcome monitoring. *Addictive Behaviors* 2019; October 8: <https://doi.org/10.1016/j.addbeh.2019.106144>.
33. Hall W, **Stjepanović D**. Commentary on Shi & Liang: Has cannabis legalization increased acute cannabis-related harms? *Addiction* in press: <https://doi.org/10.1111/add.15064>.
34. **Hall WD**. Invited paper: The costs and benefits of cannabis control policies. *Dialogues in Clinical Neuroscience*; in press.
35. **Hall WD**. Addiction Classics: The Indian Hemp Drugs Commission 1893-1894. *Addiction* 2019; 114: 1679-82.
36. **Hall WD**. Finding acceptable ways to fund research on e-cigarettes. *Addiction* 2019; 114: 375-6.
37. **Hall WD**, Darke S, Humphreys K, Marsden J, Neale J, West R. *Addiction's* policy on publishing effectiveness studies of involuntary treatment of addiction and its variants. *Addiction* 2019; December 15: <https://doi.org/10.1111/add.14933>.
38. **Hall WD**, Degenhardt L, Hickman M. Generational trends in US opioid-overdose deaths. *Nature Medicine*; in press: <https://doi.org/10.1038/s41591-020-0875-7>.
39. **Hall WD**, Gartner C, Bonevski B. Lessons from the public health responses to the US outbreak of vaping-related lung injury. *Addiction*; in press: <https://doi.org/10.1111/add.15108>.
40. **Hall WD**, Hoch E, Lorenzetti V. Cannabis use and mental health: risks and benefits. *European Archives of Psychiatry and Clinical Neuroscience* 2019; 269: 1-3.
41. **Hall WD**, Lane T. Road safety risks of cannabis use: sales need to fund research. *American Journal of Public Health*; accepted December 14: <https://doi.org/10.2105/AJPH.019.305529>.

42. **Hall WD, Leung J**, Lynskey M. The effects of cannabis use on the development of adolescents and young adults. *Annual Review of Developmental Psychology* in press; v.2.
43. **Hall WD**, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. *World Psychiatry*; in press: <https://doi.org/10.1002/wps.20735>.
44. **Hall WD**, Martin J. Increasing access to medical cannabis carries risks as well as benefits. *Lancet Psychiatry*; in press.
45. **Hall WD**, Morphet K, Gartner C. A critical analysis of Australia's ban on the sale of electronic nicotine delivery systems. *Neuroethics* 2019; March 19: <https://doi.org/10.1007/s12152-019-09402-x>.
46. **Hall WD, Stjepanović D**, Caulkins J, Lynskey M, **Leung J**, Campbell G, Degenhardt L. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. *Lancet* 2019; 394: 1580-90.
47. Hammond D, Goodman S, Wadsworth E, Rynard V, Boudreau C, **Hall WD**. Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study. *International Journal of Drug Policy*; in press: <https://doi.org/10.1016/j.drugpo.2020.102698>.
48. Hasan A, von Keller R, Friemel C, **Hall WD**, Schneider M, Koethe D, Leweke F, Strube W, Hoch E. Cannabis use and psychosis: a review of reviews. *European Archives of Psychiatry and Clinical Neuroscience* 2019; September 28: <https://doi.org/10.1007/s00406-019-1068-z>.
49. Hides L, **Chan GCK**, Dawe S, McKetin R, Kavanagh DJ, Young RMcD, Teesson M, Saunders JB. Direction of the relationship between methamphetamine use and positive psychotic symptoms in regular methamphetamine users: evidence from a prospective cohort study. *British Journal of Psychiatry*; accepted November 11: <https://doi.org/10.1192/bjp.2019.263>.
50. Hides L, Quinn C, **Chan GCK**, Cotton S, Pocuca N, **Connor JP**, Witkiewitz K, Daghli MRC, Young RMcDD, Stoyanov S, Kavanagh DJ. Telephone-based motivational interviewing enhanced with individualised personality-specific coping skills training for young people with alcohol-related injuries and illnesses accessing emergency or rest/recovery services: a randomized controlled trial (QuikFix). *Addiction*; submitted December 9: <https://doi.org/10.1111/add.15146>.
51. Hu X, Gallagher M, Loveday W, Dev A, **Connor JP**. Network analysis and visualisation of opioid prescribing data. *IEEE Journal of Biomedical and Health Informatics* 2019; September 2: <https://doi.org/10.1109/jbhi.2019.2939028>.
52. Humphreys K, **Hall WD**. Reducing the risks of distortion in cannabis research. *Addiction* 2019; 115: 799-801.
53. Kavanagh DJ, Teixeira H, Connolly J, Andrade J, May J, Godfrey S, Carroll A, Taylor K, **Connor JP**. The Motivational Thought Frequency Scales for increased physical activity and reduced high-energy snacking. *British Journal of Health Psychology*; in press: <https://doi.org/10.1111/bjhp.12422>.
54. Knox K, Dietrich T, Rundle-Thiele S, **Connor JP**. Parent and peer behavior: fueling adolescent binge drinking intentions? *Journal of Consumer Marketing* 2019; 36: 539-50.
55. Lane T, **Hall WD**. Traffic fatalities within US states that have legalized recreational cannabis sales and their neighbours. *Addiction* 2019; 114: 847-56.
56. Larance B, Campbell G, Moore T, Nielsen S, Bruno R, Lintzeris N, Cohen M, **Hall WD**, Mattick R, O'Donnell C, Degenhardt L. Concerns and help-seeking among patients using opioids for management of chronic noncancer pain. *Pain Medicine* 2019; 20: 758-69.
57. Larney S, **Hall WD**. A major expansion of opioid agonist treatment is needed to reduce overdose deaths in the USA. *Lancet Public Health* 2019; 4: e77-e8.
58. **Leung J**, Chan GCK, Hides L, **Hall WD**. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. *Addictive Behaviors*; submitted October 27: <https://doi.org/10.1016/j.addbeh.2020.106479>.
59. **Leung J, Chiu V, Chan GCK, Stjepanović D, Hall WD**. What have been the public health impacts of cannabis legalisation in the USA? A review of evidence on adverse and beneficial effects. *Current Addiction Reports* 2019; 6: 418-28.
60. **Leung J, Chiu V, Chung JYC, Hall WD, Chan GCK**. How many more young Australians say that they would use cannabis if it was legal? *Drug and Alcohol Review*; in press: <https://doi.org/10.1111/dar.13124>.
61. **Leung J, Chiu V, Connor JP**, Peacock A, Kelly A, **Hall WD, Chan GCK**. Alcohol consumption and consequences in adolescents in 68 low and middle-income countries - a multi-country comparison of risks by sex. *Drug and Alcohol Dependence* 2019; 205: 107520.
62. Lorenzetti V, Hoch E, **Hall WD**. Adolescent cannabis use, cognition, brain health and educational outcomes: a review of the evidence. *European Neuropsychopharmacology*; submitted October 3: <https://doi.org/10.1016/j.euroneuro.2020.03.012>.
63. Martin J, **Hall WD**, Fitzcharles M, Borgelt L, Crippa J. Ensuring access to safe, effective, and affordable cannabis-based medicines. *British Journal of Clinical Pharmacology*; submitted December 11: <https://doi.org/10.1111/bcp.14242>.

64. Mendelsohn C, **Hall WD**. Does the gateway theory justify a ban on nicotine vaping in Australia? *International Journal of Drug Policy*; in press: <https://doi.org/10.1016/j.drugpo.2020.102712>.
65. Mendelsohn C, **Hall WD**, Borland R. Could vaping help lower smoking rates in Australia? *Drug and Alcohol Review*; submitted October 20: <https://doi.org/10.1111/dar.13039>.
66. Mendelsohn C, **Hall WD**, Borland R. Response to Chapman and Daube: could vaping help lower smoking rates in Australia? *Drug and Alcohol Review*; in press: <https://doi.org/10.1111/dar.13066>.
67. Mewton L, Shaw B, Slade T, Birrell L, Newton NC, Chapman C, Allsop S, **Hides L**, McBride N, Andrews G, Teesson M. The comorbidity between alcohol use and internalising psychopathology in early adolescence. *Mental Health & Prevention*; accepted November 30: <https://doi.org/10.1016/j.mhp.2019.200176>.
68. Morphet K, **Weier M**, Borland R, Yong H, Gartner C. Barriers and facilitators to switching from smoking to vaping: advice from vapers. *Drug and Alcohol Review* 2019; 38: 234-43.
69. Murray RM, **Hall WD**. Will legalization and commercialization of cannabis use increase the incidence and prevalence of psychosis? *JAMA Psychiatry*; in press: <https://doi.org/10.1001/jamapsychiatry.2020.0339>.
70. Naghavi M, Orpana H, Marczak L, Arora M, Abbasi N, ..., **Leung J**, Lopez AD, et al. Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016. *BMJ* 2019; 364: 194.
71. Nielsen S, Murnion B, Campbell G, Young H, **Hall WD**. Cannabinoids for the treatment of spasticity. *Developmental Medicine and Child Neurology* 2019; 61: 631-8.
72. Norman T, Peacock A, Bruno R, **Chan GCK**, Morgan A, Voce I, Droste N, Taylor N, Coomber K, Miller P. Aggression in the Australian night time economy: A comparison of alcohol only versus alcohol and illicit drug consumption. *Drug and Alcohol Review* 2019; 38: 744-9.
73. O'Brien J, Grant S, Banks A, Bruno R, Carter S, Choi PM, Covaci A, Crosbie N, Gartner C, **Hall WD**, Jiang G, Kaserzon S, Kirkbride KP, Lai FY, Mackie R, Marshall J, Ort C, Paxman C, Prichard J, Thai P, Thomas KV, Tschärke B, Mueller JF. A National Wastewater Monitoring Program for a better understanding of public health: a case study using the Australian Census. *Environment International* 2019; 122: 400-11.
74. O'Brien J, **Hall WD**. Commentary on Burgard et al. (2019): Wastewater based estimates of the size of illicit markets for psychoactive drugs. *Addiction* 2019; 114: 1591-2.
75. **Papinczak ZE**, **Connor JP**, Feeney GFX, Harnett P, Young RMCD, **Gullo MJ**. Testing the bioSocial cognitive model of substance use in cannabis users referred to treatment. *Drug and Alcohol Dependence* 2019; 194: 216-24.
76. **Patton KA**, **Connor JP**, Sheffield J, Wood A, **Gullo MJ**. Additive effectiveness of mindfulness meditation to a school-based brief cognitive-behavioral alcohol intervention for adolescents. *Journal of Consulting and Clinical Psychology* 2019; 87: 407-21.
77. Peacock A, Bruno R, Gisev N, Degenhardt L, **Hall WD**, Sedefov R, White J, Thomas KV, Farrell M, Griffiths P. New psychoactive substances: challenges for drug surveillance, control, and public health responses. *Lancet* 2019; 394: 1668-84.
78. Peacock A, **Chiu V**, **Leung J**, Dobbins T, Larney S, Gisev N, Pearson SA, Degenhardt L. Protocol for the Data-Linkage Alcohol Cohort Study (DACs): investigating mortality, morbidity and offending among people with an alcohol-related problem using linked administrative data. *BMJ Open* 2019; 9: e030605.
79. **Piatkowski TM**, White K, **Hides LM**, Obst P. Australia's Adonis: understanding what motivates young men's lifestyle choices for enhancing their appearance. *Australian Psychologist*; accepted December 19: <https://doi.org/10.1111/ap.12451>.
80. Plenty S, Evans-Whipp T, **Chan GCK**, Kelly AB, Toumbourou J, Patton G, Hemphill S, Smith R. Predicting alcohol misuse among Australian 19-year-olds from adolescent drinking trajectories. *Substance Use and Misuse* 2019; 54: 247-56.
81. **Pocuca N**, **Hides L**, **Quinn CA**, White M, Mewton L, Loxton N. An exploratory study of the relationship between neuroticism and problematic drinking in emerging adulthood, and the moderating effect of social anxiety. *Personality and Individual Differences* 2019; 145: 132-44.
82. **Pocuca N**, **Hides L**, **Quinn CA**, White M, Mewton L, Newton N, Slade T, Chapman C, Teesson M, Andrews G, Allsop S, McBride N. The interactive effects of perceived peer drinking and personality profiles on adolescent drinking: a prospective cohort study. *Addiction* 2019; 114: 450-61.
83. **Pocuca N**, **Quinn CA**, Do L, Hides L. Social cognitive moderators of the relationship between social anxiety and alcohol outcomes in young people. *Journal of Studies on Alcohol and Drugs*; submitted May 16: <https://doi.org/10.15288/jsad.2020.81.95>.
84. Puljevic C, Coomber R, **de Andrade DF**, Kinner S. Barriers and facilitators of maintained smoking abstinence following release from smoke-free prisons: a qualitative enquiry. *International Journal of Drug Policy* 2019; 68: 9-17.
85. **Quinn CA**, Archibald K, Nykiel L, **Pocuca N**, **Hides L**, Allan J, Moloney G. Does self-efficacy moderate the effect of gambling advertising on problem gambling behaviors? *Psychology of Addictive Behaviors* 2019; 33: 503-9.
86. **Quinn CA**, Hides L, de Andrade D, **Pocuca N**, Wilson M, **Kavanagh DJ**. Impact of a brief psychoeducational intervention for reducing alcohol use and related harm in school leavers. *Drug and Alcohol Review* 2019; 38: 339-48.

87. Reiner R, Olsen H, Ikeda C, ..., **Leung J**, ..., Vos T, Murray C, Kassebaum N. Diseases, injuries, and risk factors in child and adolescent health, 1990 to 2017: findings from the Global Burden of Diseases, Injuries, and Risk Factors 2017 Study. *JAMA Pediatrics* 2019; 173: e190337.
88. **Revill AS, Patton KA, Connor JP**, Sheffield J, Wood AP, Castellanos-Ryan N, **Gullo MJ**. From Impulse to Action? Cognitive Mechanisms of Impulsivity-Related Risk for Externalizing Behavior. *Journal of Abnormal Child Psychology*; in press: <https://doi.org/10.1007/s10802-020-00642-7>.
89. Roxburgh A, **Hall WD**, Gisev N, Degenhardt L. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: comparison across opioids. *Drug and Alcohol Dependence* 2019; 205: 107533.
90. Symons M, Feeney GFX, Gallagher MR, Young RMcD, **Connor JP**. Predicting alcohol dependence treatment outcomes: a prospective comparative study of clinical psychologists versus 'trained' machine learning models. *Addiction*; submitted July 18: <https://doi.org/10.1111/add.15038>.
91. Symons M, Feeney GFX, Gallagher MR, Young RMcD, **Connor JP**. Machine learning vs addiction therapists: a pilot study predicting alcohol dependence treatment outcome from patient data in behavior therapy with adjunctive medication. *Journal of Substance Abuse Treatment* 2019; 99: 156-62.
92. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, Siahpush M, Gartner C, Walker N, Mendelsohn C, **Hall WD**, Paul C, Zwar N, Ferguson S, Boland V, Richmond R, Doran C, Shakeshaft A, Mattick R, Courtney R. The effectiveness, safety and cost-effectiveness of cytosine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. *Addiction* 2019; 114: 923-33.
93. Thomas H, Scott J, **Coates JM, Connor JP**. Development and validation of the Bullying and Cyberbullying Scale for Adolescents: a multi-dimensional measurement model. *British Journal of Educational Psychology* 2019; 89: 75-94.
94. Thorberg F, Young RMcD, Hasking P, Lyvers M, **Connor JP**, London E, Huang Y, Feeney GFX. Alexithymia and alcohol dependence: the roles of negative mood and alcohol craving. *Substance Use and Misuse* 2019; 54: 2380-6.
95. Thorberg FA, Hasking P, Huang YL, Lyvers M, Young RMcD, **Connor JP**, London ED, Feeney GFX. The influence of alexithymia on alcohol craving, health-related quality of life and gender in alcohol-dependent outpatients. *Journal of Psychoactive Drugs*; in press: <https://doi.org/10.1080/02791072.2020.1762022>.
96. Trickey A, Fraser H, Lim A, Peacock A, Colledge S, Walker J, **Leung J**, Grebely J, Larney S, Martin N, Hickman M, Degenhardt L, May M, Vickerman P. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. *Lancet Gastroenterology & Hepatology* 2019; 4: 435-44.
97. Trickey A, Fraser H, Lim A, Walker J, Peacock A, Colledge S, **Leung J**, Grebely J, Larney S, Martin N, Degenhardt L, Hickman M, May M, Vickerman P. Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: a modelling study. *Journal of Viral Hepatitis* 2019; 26: 1388-403.
98. Vallentin-Holbech L, Dalgaard Guldager J, **Dietrich T**, Rundle-Thiele S, Majgaard G, Lyk P, Stock C. Co-creating a virtual alcohol prevention simulation with young people. *International Journal of Environmental Research and Public Health*; submitted December 9: <https://doi.org/10.3390/ijerph17031097>.
99. Yucel M, Oldenhof E, Ahmed S, Belin D, Billieux J, Bowden-Jones H, Carter A, Chamberlain S, Clark L, **Connor JP**, Daghli M, Dom G, Dannon P, Duka T, Fernandez-Serrano M, Field M, Franken I, Goldstein R, Gonzalez R, Goudriaan A, Grant J, **Gullo MJ**, Hester R, Hodgins D, Le Foll B, Lee R, Lingford-Hughes A, Lorenzetti V, Moeller S, Munafo M, Odaug B, Potenza M, Segrave R, Sjoerds Z, Solowij N, van den Brink W, van Holst R, Voon V, Wiers R, Fontenelle L, Verdejo-Garcia A. A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. *Addiction* 2019; 114: 1095-109.
100. Zheng Q, Tschärke B, Krapp C, O'Brien J, Mackie R, **Connor JP**, Mueller J, Thomas K, Thai PK. New approach for the measurement of long-term alcohol consumption trends: application of wastewater-based epidemiology in an Australian regional city. *Drug and Alcohol Dependence* 2019; December 11: <https://doi.org/10.1016/j.drugalcdep.2019.107795>.

## Books and Book Chapters

1. Barnett A, **Hall WD**, Carter A. Disease, wellness, and addiction: a global perspective. In: Stein D, Singh I, editors. *Global Mental Health and Neuroethics* (pp.211-24). Oxford: Oxford University Press, in press.
2. **Coates JM**, Feeney GFX, **Gullo MJ**, **Kavanagh DJ**, Young RMcD, May J, Andrade J, **Connor JP**. Craving measurement and application of the Alcohol Craving Experience questionnaire. In: Preedy V, editor. *The Neuroscience of Alcohol: Mechanisms and Treatment* (pp.603-10). London: Academic Press, 2019.
3. **Connor JP**, **Weier M**, **Hall WD**. Age of onset of alcohol use disorders. In: de Girolamo G, McGorry P, Sartorius N, editors. *The Age of Onset of Mental Disorders: Ethio-pathogenetic and Treatment Implications* (pp.169-82). Basel: Springer International Publishing AG, 2019.
4. Dawson A, Chandler J, Gavaghan C, **Hall WD**, Carter A. Neuropsychiatric evidence as a mitigating factor in sentencing offenders with addictive behaviours. In: Vincent N, Nadelhoffer T, McCay A, editors. *Neurointerventions and the Law: Regulating Human Mental Capacity* Oxford: Oxford University Press, in press.
5. Dawson A, **Hall WD**, Carter A. Cognitive research on addiction in a changing policy landscape. In: Verdejo-Garcia A, editor. *Cognition and Addiction: A Researcher's Guide from Mechanisms Towards Interventions* (pp.321-9). London: Academic Press Ltd- Elsevier Science Ltd, 2019.
6. Gartner C, **Hall WD**. Lessons from tobacco regulation for cannabis product regulation. In: Decorte T, Lenton S, Wilkins C, editors. *Legalizing cannabis: experiences, lessons and scenarios* (pp.233-58). Abingdon, UK: Routledge, in press.
7. **Hall WD**. Thematic Chapter: Cannabis and cannabinoids for medical, scientific and "recreational" use: risks and benefits. *Report of the International Narcotics Control Board for 2018* (pp.1-12). Vienna: United Nations; March 5, 2019.
8. **Hall WD**. Foreword. In: Hoch E, Friemel CM, Schnieder M, editors. *Cannabis: Potenzial and Risiko: Eine Wissenschaftliche Bestandsaufnahme* (pp.v-vi). Berlin: Springer Verlag for Bundesministerium for Gesundheit, 2019.
9. Kelly AB, **Thomas R**, **Chan GCK**. Nicotine use and weight control in young people: implications for prevention and early intervention. *Neuroscience of Nicotine: Mechanisms and Treatment* (pp.451-8). London: Elsevier; SCOPUS, 2019.
10. **Kelly AB**, **Weier M**, **Hall WD**. Age of onset of substance use disorders. In: de Girolamo G, McGorry P, Sartorius N, editors. *The Age of Onset of Mental Disorders: Ethio-pathogenetic and Treatment Implications* (pp.149-67). Basel: Springer International Publishing AG, 2019.
11. Leung J, **Hall WD**, Degenhardt L. Adolescent cannabis use disorders. In: Essau CA, Delfabbro P, editors. *Adolescent Addiction: Epidemiology, Assessment, and Treatment* (pp.111-35). London: Academic Press/ Elsevier; 2nd, in press.
12. Peacock A, **Hall WD**, Degenhardt L. Epidemiology of substance use internationally. In: Sloboda Z, Petras H, Robertson E, Hingson R, editors. *Prevention of Substance Use* (pp.19-36). Cham, Switzerland: Springer, 2019.
13. Steindl S, **Connor JP**. Enhancing treatment engagement through motivational interviewing. In: Hadler A, Sutton S, Osterberg L, editors. *The Wiley Blackwell handbook of treatment engagement: theory, research and clinical practice* Oxford: John Wiley, in press.

## Meeting papers and invited presentations in 2019


1. **Hall WD.** Invited lecture: Recent developments in cannabis legalisation in the Americas: what is happening and what may happen? School of Public Health, University of Queensland, March.
2. **Hall WD.** Invited lecture: Recent developments in cannabis legalisation in the Americas: what has happened and what may happen in future? National Addiction Centre, Kings College London, May.
3. **Hall WD.** Invited paper: The Australian approach to medical cannabis. Med-Cannabis 2019: Second International Annual Congress on Controversies in Cannabis-based Medicines, Barcelona, Spain, May 23-24.
4. **Hall WD.** Invited lecture: Recent developments in medical cannabis in the UK and Europe. Australian Advisory Council on Medical Uses of Cannabis, Melbourne, June.
5. Hu X, Gallagher M, Loveday W, **Connor JP.** Advanced data analysis of controlled drug prescribing data. Brisbane Life Science ECR Symposium (BLISS), Brisbane, June 7.
6. **Pocuca N, Hides L, Quinn CA,** Mewton L, Newton NC, Slade T, Chapman C, Andrews G, Teesson M, Birrell L, Allsop S, McBride N. The moderating effect of impulsivity on the relationship between anxiety sensitivity and drinking to intoxication in young people Abstract of paper presented at the 42nd Annual Scientific Meeting of the Research Society on Alcoholism, June 22-26, 2019 — Minneapolis, Minnesota. *Alcoholism-Clinical and Experimental Research*, June 2019; 43: 57A. Available from: <https://onlinelibrary.wiley.com/doi/epdf/10.1111/acer.14059>.
7. **Connor JP.** Assessment of Alcohol Use Disorders: evidence review for 2020 Commonwealth funded update to the National Guidelines for Treatment of Alcohol Problems. National Guidelines for Treatment of Alcohol Use Disorders symposium, University of Sydney, July 2019.
8. **Gullo MJ.** Psychosocial Interventions for Alcohol Use Disorders: evidence review for 2020 Commonwealth funded update to the National Guidelines for Treatment of Alcohol Problems. National Guidelines for Treatment of Alcohol Use Disorders symposium, University of Sydney, July 2019.
9. **Gullo MJ, Patton KA, Connor JP,** Sheffield J, Wood A. Additive effectiveness of mindfulness meditation to a school-based brief cognitive-behavioral alcohol intervention for adolescents. Proceedings of the 9th World Congress of Behavioural and Cognitive Therapies (WCBCT), Berlin, July 17-20. <https://wcbct2019.org/Downloads/abstract-book-1.pdf>.
10. **Hides L, Kavanagh D, Quinn C, Chan GCK, Cotton S, Daghli M, Mergard L, Young RMCD.** Randomized controlled trial of personality risk-targeted coping skills training for young people with alcohol related-illnesses/injuries. Proceedings of the 9th World Congress of Behavioural and Cognitive Therapies (WCBCT), Berlin, July 17-20. <https://wcbct2019.org/Downloads/abstract-book-1.pdf>.
11. **Hall WD.** Global developments in medical uses of cannabis and cannabinoids. Second Annual Scientific Meeting of Australian Centre for Cannabinoid Clinical and Research Excellence (NHMRC CRE), University of Wollongong, NSW, July.
12. **Hall WD.** Invited lecture. Cannabis legalisation in the Americas: what has happened and what may happen to cannabis use and public health harm? National Drug and Alcohol Research Centre, University of New South Wales, August.
13. **Hall WD.** CYSAR Symposium. Cannabis legalisation in the Americas: what has happened and what may happen to cannabis use and public health harm? Queensland Brain Institute and Centre for Youth Substance Abuse Research, University of Queensland, September 4.
14. **Hall WD.** Dealing with the media. Health and Behavioral Sciences Seminar, University of Queensland, September.
15. **Hall WD.** Cannabis policy experiments in the Americas: what have we learned so far? RAND Europe, Cambridge, England, October.
16. **Hall WD.** The Indian Hemp Drugs Commission 1894: the uses of history in contemporary drug policy debates. London School of Hygiene and Tropical Medicine, London, October.
17. **Hall WD.** Improving assessments of the quantity and frequency of recreational cannabis use: do not allow the ideal to be the enemy of the good. International Cannabis Toolkit Workshop 2019- a side event of the Lisbon Addictions conference (23rd - 25th October), Lisbon, Portugal, October 22. <https://canntoolkit.com/programme/>.
18. **Hall WD.** The great debate: Will changes in cannabis policy result in greater costs or greater benefits? Lisbon Addictions Conference, October 23. <https://www.lisbonaddictions.eu/lisbon-addictions-2019/sessions/will-changes-cannabis-policy-result-greater-costs-or-greater-benefits>.

19. **Hall WD.** Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Launch of *The Lancet* review series: "Using evidence to better respond to drug problems - a call for action". Lisbon Addictions Conference, October 24. <https://www.lisbonaddictions.eu/lisbon-addictions-2019/presentations/public-health-implications-legalising-production-and-sale-cannabis-medicinal-and>.
20. **Hall WD.** How have policies for legal medical and recreational cannabis shaped the development of new cannabis products? Lisbon Addictions Conference, October 24. <https://www.lisbonaddictions.eu/lisbon-addictions-2019/presentations/how-have-policies-legal-medical-and-recreational-cannabis-shaped-development-new>.
21. **Hall WD.** Mobilising evidence-based secondary prevention for cannabis use in legalisation contexts: The Lower-Risk Cannabis Use Guidelines (LRCUG) (oral presentation). Lisbon Addictions Conference, October 24. <https://www.lisbonaddictions.eu/lisbon-addictions-2019/presentations/mobilising-evidence-based-secondary-prevention-cannabis-use-legalisation-contexts>.
22. Gullo MJ. Inducing impulsive states to increase laboratory alcohol consumption in young adults. Inaugural UQ Behavioural and Economic Science Cluster cross-faculty workshop on social science experiments, October 28. <https://economics.uq.edu.au/event/session/7183>.
23. **Hall WD.** The US outbreak of lung injuries related to vaping. Australian Council on Medical Uses of Cannabis, Melbourne, November.
24. **Gullo MJ, Papinczak, ZE, Connor JP,** Feeney GFX. Additive effectiveness of an electronic Instant Assessment and Feedback (iAx) system for brief cannabis intervention in a public hospital clinic. Poster presented at 8th Annual National Health and Medical Research Council (NHMRC) Symposium: Research Translation in the Digital Age: Harnessing the Power of Data and Analytical Technologies, Melbourne, November 18.
25. Barnett A, O'Brien K, Dilkes-Frayne E, **Hall WD,** Carter A. Differing views about the disease and brain disease model of addiction: an international survey of addiction treatment providers in the USA, United Kingdom and Australia. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 201). *Drug and Alcohol Review*, Nov 2019; 38: s25. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
26. Black N, Stockings E, Tran L, Campbell G, Zagic D, **Hall WD,** Farrell M, Degenhardt L. Cannabis and cannabinoids for the treatment of mental disorders and symptoms: a systematic review and meta-analysis. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 128). *Drug and Alcohol Review*, Nov 2019; 38: s28. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
27. **Bryant SJ, Gullo MJ.** Impulsivity and alcohol use in youth: unravelling the key causal mechanisms. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 163). *Drug and Alcohol Review*, Nov 2019; 38: s33. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
28. Campbell G, **Hall WD,** Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Noghrehchi F, Mattick R, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L. Problematic opioid use in people prescribed opioids for chronic non-cancer pain over five years: a prospective cohort study. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 237). *Drug and Alcohol Review*, Nov 2019; 38: s34. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
29. **Chan GCK,** Becker D, Butterworth P, Coffey C, **Hall WD,** Patton G. The consequences of late and early onset regular cannabis use: findings from a 20-year Australian prospective study. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 145). *Drug and Alcohol Review*, Nov 2019; 38: s35. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
30. **Chiu V, Leung J, Chan GCK, Hall WD, Hides L.** Personal correlates of support for medical cannabis legalisation in Australia. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 70). *Drug and Alcohol Review*, Nov 2019; 38: s36. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
31. **Hides L, Quinn C, Chan GCK, Pocuca N,** Cotton S, **Connor JP,** Daghli M, Mergard L, Young RMCD, **Kavanagh DJ.** Symposium- Presentation 2: Final results of a randomised controlled trial of personality risk-targeted coping skills training for young people with alcohol related-illnesses/injuries. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November. *Drug and Alcohol Review*, Nov 2019; 38: s18. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.

- 32. Leung J, Chan GCK, Hides L, Hall WD.** What risk do cannabis users run of developing cannabis use disorders? A systematic review and meta-analysis. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 35). *Drug and Alcohol Review*, Nov 2019; 38: s65. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 33. Papinczak ZE, Connor JP, Feeney GFX, Gullo MJ.** Additive effectiveness of the instant assessment and feedback system as an adjunct to a brief intervention for cannabis users (Paper 5). Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November. *Drug and Alcohol Review*, Nov 2019; 38: s80. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 34. Peacock A, Chiu V, Leung J, Dobbins T, Larney S, Gisev N, Pearson S, Dunlop A, Degenhardt L.** Characterising people attending New South Wales emergency departments and hospitals for an alcohol-related problem, 2005-2014: the Data-Linkage Alcohol Cohort Study. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 177) *Drug and Alcohol Review*, Nov 2019; 38: s81. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 35. Quinn C, Hides L, Walters Z, De Andrade D, Connor JP.** Symposium Presentation 4 - A strength-based wellbeing recovery program for young people accessing residential rehabilitation for substance use disorders. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November. *Drug and Alcohol Review*, Nov 2019; 38: s19. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 36. Quinn C, Hides L, Walters Z, Riordan B, De Andrade D, Connor JP, Merrill J, Ward R, Chan GCK, Pocuca N, Cotton S, Daghli M, Mergard L, Young RMcD, Kavanagh DJ.** Symposium: Novel approaches to address the complexities of youth substance use (Paper 184). Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November. *Drug and Alcohol Review*, Nov 2019; 38: s17-s8. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 37. Walters Z, Hides L, Pocuca N.** Symposium Presentation 3 -Mechanisms of change in an integrated cognitive behaviour therapy treatment program for co-occurring depression and substance misuse in young people. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Symposium presentation 3). *Drug and Alcohol Review*, Nov 2019; 38: s18-s9. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 38. Yuen WS, Chan GCK, Clare P, Bruno R, Boland V, Aiken A, Kypri K, Horwood J, McCambridge J, Degenhardt L, Slade T, Wadolowski M, Hutchinson D, Najman J, McBride N, Mattick R, Peacock A.** Trajectories of adolescent alcohol consumption: a prospective cohort study. Abstract of paper presented at the APSAD Scientific Alcohol and Drug Conference, Hobart 10-13 November (Paper 57). *Drug and Alcohol Review*, Nov 2019; 38: s107. Available from: <https://onlinelibrary.wiley.com/toc/14653362/2019/38/S1>.
- 39. Hall WD.** Approaches to preventing cannabis use and cannabis related harm. World Health Organization, Meeting of Technical Experts on Cannabis, Geneva (via teleconference), December.
- 40. Hall WD.** The US outbreak of vaping-related lung diseases: probable cause and policy responses. Centre for Youth Substance Abuse Research, University of Queensland, December 5.

# Our People

6



## Staff Listing

Centre Staff Name	Appointment Type	Description
Dr Gary Chan, NHMRC Investigator Emerging Leadership Fellow	Academic	Level B, 1.0, partly supported by UQ Fellowship, NHMRC Fellowship awarded August 2019 for 2020-2025
Dr Jason Coates, Research Fellow	Academic	Level B, 0.2 FTE
Professor Jason Connor, Director	Academic	Level E, 0.7 FTE; Inaugural Director 2008-2013; 2017-current, seconded to HaBS from UQ Faculty of Medicine
Associate Professor Matthew Gullo, MRFF Translating Research into Practice Fellow	Academic	Level C; promoted to Level D Sept 2019 round; effective Jan 2020, 1.0
Professor Wayne Hall, Professorial Research Fellow	Academic	Level E, 0.2 FTE
Dr Daniel Stjepanović, Research Fellow	Academic	Level B, 1.0
Ms Sarah Yeates, Senior Research Assistant	Professional	HEW 7, 0.7 FTE
Professor Annemaree Carroll	Affiliate	Associate Dean, Research, HASS Faculty, UQ
Dr Dominique De Andrade	Affiliate	LLW Research Fellow, School of Psychology, UQ
Dr Timo Dietrich	Adjunct	Social Marketing @ Griffith University
A/Professor Genevieve Dingle	Affiliate	School of Psychology, UQ
Associate Professor Gerald F. X. Feeney	Adjunct	Alcohol and Drug Assessment Unit, Princess Alexandra Hospital
Ms Carrie Fowlie	Adjunct	Executive Officer, Alcohol Tobacco and Other Drug Association ACT (ATODA)

## Staff Listing (continued)

Centre Staff Name	Appointment Type	Description
Mr Cameron Francis	Adjunct	Social Worker and Team Leader, Dovetail, Queensland Health
Professor Leanne Hides, Deputy Director	Affiliate	Lives Lived Well (LLW) Chair, School of Psychology, UQ
Mr John Kelly	Adjunct	Alcohol and Drug Service, Metro North Hospital and Health Service
Dr Janni Leung	Affiliate	UQ Development Fellow at LLW Group, School of Psychology, UQ
Dr Natalie Loxton	Honorary	Senior Lecturer, School of Applied Psychology, Griffith University
A/Professor Louise McCuaig	Affiliate	School of Human Movement and Nutrition Sciences, UQ
Dr Carla Meurk	Adjunct	Queensland Forensic Mental Health Service, Queensland Health
Dr Catherine Quinn	Affiliate	LLW Research Fellow, School of Psychology, UQ
Professor Sharyn Rundle-Thiele	Honorary Professor	Social Marketing @ Griffith University
Professor John Saunders	Honorary Professor	Professor and Consultant Physician in Internal Medicine and Addiction Medicine, Sydney
Dr Megan Weier	Honorary	Research Associate, Centre for Social Impact, UNSW
Dr Andrew Wood	Adjunct	Lecturer, Clinical Psychology, University of the Sunshine Coast

## Our Students

### Research Higher Degrees Completed in 2019

Student	Supervisors	Title	Degree
Nina Pocuca (QUT)	Hides, Quinn, White, Mewton	Examination of personality risk profiles and alcohol use in young people	PhD
Zoe Papinczak	Gullo, Connor, Harnett	A bioSocial cognitive model of youth cannabis dependence	PhD

### Commencing in January 2020

Student	Supervisors	Title	Degree
Carmen Lim	Chan, Leung, Connor, Gartner	Personal vaporiser use - quantifying the benefits and harms on the population	PhD
Tianze Sun	Chan, Leung, Connor, Gartner	Electronic cigarette and vaping - psychosocial profiles and impact on mental health.	PhD

## Our Students

### Research Higher Degrees Ongoing

Student	Supervisors	Title	Degree
Angela Wanigasooriya	Gullo, Connor	Social cognitive predictors of treatment outcomes for amphetamine use and application of a bioSocial cognitive model	PhD
Sarah Bryant	Gullo, Harnett	Investigating social-cognitive predictors of alcohol misuse and related risky behaviours among adolescents	PhD
Vivian Chui Ying Chui	Leung, Chan, Hall, Hides	The impacts of legalisation of medical and recreational cannabis	PhD
Laura Anderson	Gullo, Dingle	Preventing sexually transmitted infections in adolescents: A targeted approach	PhD
Annaketurah Ralph	Gullo, Connor, Harnett	The relationship between childhood trauma, attachment style, impulsivity and substance use disorders in adolescents	PhD
Rebekah Thomas	Kelly, Chan	Exploring socio-emotional markers and the development of emerging eating disorder throughout adolescence	PhD
Tim Piatkowski	Hides	Exploring the relationship between self-concept, social influences, body image, and substance use among young men within a Bruss sub-culture	PhD

# Major Partners *and* Collaborators

7



## Research

CYSAR has extensive collaborations and links with other *national* and *international* researchers in the alcohol and other drug field.

### In Australia

Commonwealth Department of Health and Ageing (ACT)  
Griffith University (Qld)

National Centre for Education and Training on Addiction (NCETA) National Drug and Alcohol Research Centre (NDARC) (NSW) National Drug Research Institute, Curtin University

Deakin University (Vic)

Turning Point Alcohol and Drug Centre (Vic)

Centre for Adolescent Health, Murdoch Children's Research Institute (Vic) Orygen Youth Health Research Centre (Vic)

### International

European Monitoring Centre on Drugs and Drug Addiction

King's College London, National Addiction Centre, Institute of Psychiatry London School of Hygiene & Tropical Medicine

RAND Corporation Drug Policy Research Centre, Santa Monica, California United Nations Office on Drugs and Crime

University of California, Los Angeles University of Otago

University of Plymouth University of Strathclyde University of Vienna

University of Washington- Alcohol and Drug Abuse Institute World Bank

World Health Organization (Expert Committee on Drug Dependence) Industry and Clinical

CYSAR has a number of well-established industry and clinical partners across the drug and alcohol, mental health, emergency, housing and social support sectors. Representatives of many of these services are represented on the CYSAR Advisory Board and have formal UQ affiliate joint appointments with the Centre.

**Alcohol and Drug Assessment Unit, Princess Alexandra Hospital**

The Alcohol and Drug Assessment Unit (ADAU) is a multidisciplinary outpatient Liaison Clinical Service at a large Australian metropolitan university teaching hospital. The team of doctors, nurses, social workers and psychologists offers assessment and management of substance misuse and problems related to addiction treatment programs for alcohol, tobacco, cannabis, and stimulants. They follow best practice in alcohol and drug treatment, education, research and addictions medicine.

**Brisbane Catholic Education**

CYSAR partners with BCE to deliver innovative social marketing programs in schools to combat alcohol-related problems. Key components of ARC Linkage Grant funded programs are now embedded in the curriculum of 183 schools in QLD.

**Brisbane Youth Services (BYS)**

BYS supports homeless and disadvantaged young people (aged 12-25 years) and their children, to secure and maintain housing. They provide emergency support and a range of services to assist young people to address physical and mental health issues, establish successful relationships and support networks, and access education and long term employment.

**ChaplainWatch Inc.**

ChaplainWatch is an independent Brisbane-based charity, focused on public safety in public spaces. It provides a unique, non-authoritarian service, which encompasses crisis intervention, conflict resolution, front-line first aid, counselling and guidance, secondary victim support, and welfare assistance. This rapid response service works in partnership with other official services. ChaplainWatch are a key partner in the Quikfix early intervention project.

### **CHQ Children & Youth Mental Health Services (CYMHS)**

CYMHS at Children's Health Queensland specialises in helping infants, children and young people up to the age of 18 years who have complex mental health and drug and alcohol needs. CYMHS are a key partner on the Quikfix early intervention research program.

### **Drug & Alcohol Brief Intervention Team (DABIT; Queensland Health)**

Based at key QLD hospitals, the DABIT service model is based on successful services overseas, and targets people with alcohol and drug problems not currently in treatment. Young people attending emergency departments often have substance use problems. For example, road trauma, assaults and injuries are often associated with high risk drinking and other drug usage. By providing targeted brief interventions, DABIT can reduce the likelihood of patients progressing from substance use to substance dependence. Professor Hides will implement and evaluate the evidence-based Quikfix early intervention model in these services.

### **Mater Health Adolescent Drug & Alcohol Withdrawal Service (ADAWS)**

ADAWS supports young people through individualised and group support, brief interventions, relapse prevention planning and alternative drug-free activities. The service also aims to reduce drug-related harm by utilising harm reduction strategies that take into account personal goals and choices. ADAWS are a key implementation site of the Quikfix early intervention program and are involved in a number of other treatment studies.

### **Lives Lived Well (LLW)**

LLW is the body that auspices the non-government drug and alcohol treatment sector in Queensland. It has a strong focus on young people, Aboriginal and Torres Strait Islander people, and families.

### **Dovetail**

Dovetail is the auspicing body that provides clinical advice and professional support to workers, services and communities across Queensland who engage with young people affected by alcohol and other drug use.

### **Queensland Alcohol & Drug Information Service (ADIS; Queensland Health)**

ADIS provides people with a range of interventions that influence and support the decision to reduce or cease harmful substance use. Referrals to alcohol and other drugs services can come from the individual experiencing the problem, family and friends, community services, Hospital and Health Services, GPs, Police, Courts and Corrective Services.

### **Queensland Injury Surveillance Unit (QISU; Queensland Health/Mater Health)**

Since 1988, Queensland Injury Surveillance Unit (QISU) continuously collects urban injury data from major Brisbane's hospitals, as well as periodically collecting rural data. It has strong collaborations with CYSAR and Professor Hides in her work on preventable youth alcohol and drug injuries.

## Scientific Advisory Board

**Professor Christina Lee**, Chair (Associate Dean [Research], Faculty of Health & Behavioural Sciences, UQ)

---

**Associate Professor Nicholas Carah** (Deputy Head, School of Communication and Arts, UQ)

**Professor Jason Connor** (Director, Centre for Youth Substance Abuse Research UQ)

**Mr Cameron Francis** (Team Leader, Dovetail, Queensland Health)

**Ms Carrie Fowlie** (Executive Officer, Alcohol Tobacco and Other Drug Association, ACT)

**Mr Mitchell Giles** (CEO, Lives Lived Well)

**Professor Leanne Hides** (Lives Lived Well Chair in Alcohol, Drugs, and Mental Health, UQ)

**Professor David Kavanagh** (Team Leader, Addiction and e-Psychology Research, Institute of Health and Biomedical Innovation, QUT)

**Ms Rebecca Lang** (Chief Executive Officer, Qld Network of Alcohol & Other Drug Agencies)

**Professor Doune Macdonald** (Pro-Vice-Chancellor [Teaching & Learning] UQ)

**Ms Liz Minchin** (Executive Editor, The Conversation Australia and New Zealand)

**Professor Ross Young** (Executive Dean, Faculty of Health, QUT)



## The Centre for Youth Substance Abuse Research

17 Upland Road, St Lucia Qld 4072

Tel: +61 344 32536

[cysar@uq.edu.au](mailto:cysar@uq.edu.au)

[www.cysar.health.uq.edu.au](http://www.cysar.health.uq.edu.au)



CREATE CHANGE